ARTICLE | Management Tracks
Plus: Amoolya Singh named CTO of Delfi and updates from Torl, OSE and George Clinical
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
December 3, 2024 12:47 AM UTC
Scott Wolchko will retire on Dec. 31 as president and CEO of Fate Therapeutics Inc. (NASDAQ:FATE), which is developing off-the-shelf cell therapies derived from induced pluripotent stem cells. President of R&D Bob Valamehr, a Fate veteran of nearly 15 years, will succeed Wolchko.
Liquid biopsy company Delfi Diagnostics Inc. hired Amoolya Singh as CTO. Singh was SVP of data science and CSO of Grail Inc. (NASDAQ:GRAL)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654358/bob-valamehr-to-succeed-ceo-scott-wolchko-at-fate